Use of intranasal live attenuated influenza vaccine in individuals with asthma or a history of wheezing
نویسنده
چکیده
In their review of live attenuated influenza vaccine (LAIV), Esposito et al. stated that in the US and Europe, LAIV is not recommended for children and adults with asthma and children younger than 5 years of age with a history of recurrent wheezing. While this statement is accurate for the US, it is not accurate for the European Union. The European Medicines Agency approved LAIV for use in children and adolescents 24 months to younger than 18 years of age, with a warning against use in children and adolescents with severe asthma or active wheezing because these individuals have not been adequately studied in clinical studies. However, based on studies that have been conducted, in the European Union there is no warning against LAIV use in children and adolescents with mild to moderate asthma or a history of recurrent wheezing. In the European Union, LAIV is not approved for use in adults 18 years of age and older.
منابع مشابه
Adverse events reported following live, cold-adapted, intranasal influenza vaccine.
CONTEXT In June 2003, the US Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20 228 vaccinees, clinical trials were not of sufficient size to detect rare adverse events reliably. OBJECTIVE To identify adverse events reported following LAIV...
متن کاملLive attenuated versus inactivated influenza vaccine in infants and young children.
BACKGROUND Universal vaccination of children 6 to 59 months of age with trivalent inactivated influenza vaccine has recently been recommended by U.S. advisory bodies. To evaluate alternative vaccine approaches, we compared the safety and efficacy of intranasally administered live attenuated influenza vaccine with those of inactivated vaccine in infants and young children. METHODS Children 6 t...
متن کاملEffectiveness and safety of seasonal influenza vaccination in children with underlying respiratory diseases and allergy
Influenza causes acute respiratory infections and various complications. Children in the high-risk group have higher complication and hospitalization rates than high-risk elderly individuals. Influenza prevention in children is important, as they can be a source infection spread in their communities. Influenza vaccination is strongly recommended for high-risk children with chronic underlying ci...
متن کاملUse of N-trimethyl chitosan for intranasal delivery of DNA encoding M2e-HSP70c in mice
BACKGROUND: Influenza outbreak has become a great lifethreateningdisease in the world. Nasal vaccines can inducesystemic IgG and mucosal IgA antibody responses, whichestablish two layers of immune defense against the infectiouspathogens like influenza. Mucosal vaccines must overcomeseveral limitations, including the mucociliary clearance andinefficient uptake of soluble antigens. Therefore, nas...
متن کاملRequirements of New Vaccines against Novel Influenza Viruses
The currently available influenza vaccines were developed in the 1930s through the 1960s using technologies that were state-of-the art for the times. Decades of advancement in virology and immunology have provided the tools for making better vaccines against influenza virus. Among young children, live attenuated vaccine had significantly better efficacy than inactivated vaccine. An evaluation o...
متن کامل